---
title: "Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284392137.md"
description: "Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News"
datetime: "2026-04-28T05:05:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284392137.md)
  - [en](https://longbridge.com/en/news/284392137.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284392137.md)
---

# Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration | PTGX Stock News

### Related Stocks

- [TAK.US](https://longbridge.com/en/quote/TAK.US.md)
- [PTGX.US](https://longbridge.com/en/quote/PTGX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [4502.JP](https://longbridge.com/en/quote/4502.JP.md)

## Related News & Research

- [Takeda Pharmaceutical (NYSE:TAK) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPS](https://longbridge.com/en/news/286621568.md)
- [Takeda Pharmaceutical - Currently Assessing Amount Of Provision To Be Recognized In Group Earnings For FY Ended March 31](https://longbridge.com/en/news/286837374.md)
- [US jury to decide if Takeda delayed generic constipation drug](https://longbridge.com/en/news/286455075.md)
- [Takeda's Next Wave Of Drugs Has Investors Watching Closely](https://longbridge.com/en/news/286288778.md)
- [Zentalis to Present Phase 1b MUIR Data: 39% ORR, 7.3‑month PFS; 50% ORR at 250 mg Cohort](https://longbridge.com/en/news/287276070.md)